Cargando…

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

BACKGROUND: Tyrosine kinase domain (TKD) mutation and particularly exon 20 insertion mutations of ERBB2 have been extensively reported in non‐small cell lung cancer (NSCLC). Due to the increased accessibility of next‐generation sequencing, more ERBB2 mutations within the non‐TKD can be detected in c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Xue‐Wu, Gao, Xin, Zhang, Xu‐Chao, Yang, Jin‐Ji, Chen, Zhi‐Hong, Wu, Yi‐Long, Zhou, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262945/ https://www.ncbi.nlm.nih.gov/pubmed/32291971 http://dx.doi.org/10.1111/1759-7714.13419

Ejemplares similares

Clinical and molecular characteristics of Chinese non‐small cell lung cancer patients with ERBB2 transmembrane domain mutations
por: Fan, Yun, et al.
Publicado: (2020)

Germline ERBB3 mutation in familial non-small-cell lung carcinoma: expanding ErbB’s role in oncogenesis
por: McInerney-Leo, Aideen M, et al.
Publicado: (2021)

Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research
por: Cardillo, Anthony B., et al.
Publicado: (2023)

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
por: Gao, Xin, et al.
Publicado: (2020)

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
por: Liu, Si-Yang, et al.
Publicado: (2020)

The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
por: Hu, Xilin, et al.
Publicado: (2021)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer
por: Fan, Zhisong, et al.
Publicado: (2022)

Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation
por: Wu, Yanyan, et al.
Publicado: (2020)

Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay
por: Su, Jian, et al.
Publicado: (2014)

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
por: Tu, Hai‐Yan, et al.
Publicado: (2023)

Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC)
por: Zhou, Ya-jun, et al.
Publicado: (2021)

Mutational landscape of homologous recombination‐related genes in small‐cell lung cancer
por: Wu, Shuo, et al.
Publicado: (2022)

Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation
por: Xu, Chong‐Rui, et al.
Publicado: (2016)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
por: Wang, Debby D., et al.
Publicado: (2015)

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
por: Yuan, Min, et al.
Publicado: (2019)

Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report
por: Ni, Jun, et al.
Publicado: (2021)

Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
por: Gao, Hong-Fei, et al.
Publicado: (2016)

Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer
por: Yang, Xiao-Rong, et al.
Publicado: (2020)

Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer
por: Yang, Lei, et al.
Publicado: (2021)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
por: Peng, Xiao-Xiao, et al.
Publicado: (2020)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
por: Gou, Lan-Ying, et al.
Publicado: (2014)

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Gou, Lan-Ying, et al.
Publicado: (2016)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report
por: Chen, Sixian, et al.
Publicado: (2021)

The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer
por: Desai, Alisha, et al.
Publicado: (2022)

ERBB2 exon 20 insertions are rare in Brazilian non‐small cell lung cancer
por: de Oliveira Cavagna, Rodrigo, et al.
Publicado: (2022)

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors
por: Wang, Hao, et al.
Publicado: (2022)

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer
por: Kang, Jin, et al.
Publicado: (2020)

The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China
por: Zhou, Qi-Ming, et al.
Publicado: (2013)

Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
por: An, She-Juan, et al.
Publicado: (2012)

BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification
por: Jiang, Ben-yuan, et al.
Publicado: (2013)

Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers
por: Zhang, Jia−Tao, et al.
Publicado: (2022)

Exosomal ERBB2IP contributes to tumor growth via elevating PSAT1 expression in non‐small cell lung carcinoma
por: Peng, Xijuan, et al.
Publicado: (2023)

Emerging therapies for non-small cell lung cancer
por: Zhang, Chao, et al.
Publicado: (2019)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Distribution and prognosis of uncommon metastases from non-small cell lung cancer
por: Niu, Fei-Yu, et al.
Publicado: (2016)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_efrkaq8v0euov9um59dlf1omqd